Rojas, F.; Parra, E.R.; Wistuba, I.I.; Haymaker, C.; Solis Soto, L.M.
Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. Cancers 2022, 14, 2775.
https://doi.org/10.3390/cancers14112775
AMA Style
Rojas F, Parra ER, Wistuba II, Haymaker C, Solis Soto LM.
Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. Cancers. 2022; 14(11):2775.
https://doi.org/10.3390/cancers14112775
Chicago/Turabian Style
Rojas, Frank, Edwin Roger Parra, Ignacio Ivan Wistuba, Cara Haymaker, and Luisa Maren Solis Soto.
2022. "Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors" Cancers 14, no. 11: 2775.
https://doi.org/10.3390/cancers14112775
APA Style
Rojas, F., Parra, E. R., Wistuba, I. I., Haymaker, C., & Solis Soto, L. M.
(2022). Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. Cancers, 14(11), 2775.
https://doi.org/10.3390/cancers14112775